Manhattan Research lists top sites

Share this article:
Two diabetes product sites, Merck's Januvia and Takeda's Actos, came in first and second, respectively, in a new study measuring physicians' web habits. 

The study, conducted by Manhattan Research, ranked drug product sites based on visitation rates from physicians. Merck had the most products on the list, at three, which included Gardasil's (#4) and Vytorin's (#6) sites. Pfizer's Chantix held the number three spot.

Actonel, an osteoporosis treatment marketed through a Proctor & Gamble/Sanofi-Aventis partnership, was ranked at number five. Seven through 10: Amitiza (#7), from Sucampo Pharmaceuticals/Takeda; Byetta (#8), an Amylin/Lilly product; Avandia (#9), a GlaxoSmithKline product; and Aciphex (#10), an Eisai/PriCara product.

“The presence of diabetes treatment products Januvia, Actos, Byetta and Avandia on the list of pharmaceutical sites most visited by primary care physicians highlight that market events, for the most part beyond a brand team's control, can be a major influence on visitation rates,” said Meredith Abreu Ressi, VP of research, Manhattan Research. “Many of the sites on the list maintain search engine marketing campaigns, making it easier for brands to get the most up to date and accurate brand content and news in front of physician searchers. Januvia's brand site, for example, presents rich media content, a plethora of educational materials about the product and diabetes, treatment tools, and more.”
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?